NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech, and Digital Health


On March 18, 2024, during GTC, NVIDIA unveiled over twenty-five new microservices designed to empower healthcare enterprises worldwide with cutting-edge generative AI capabilities. These microservices offer optimized NVIDIA NIM™ AI models and workflows, complete with industry-standard APIs, enabling the creation and deployment of cloud-native applications across various healthcare sectors.

Included in this suite are advanced imaging, natural language processing, speech recognition, and digital biology generation tools, facilitating tasks such as drug discovery, medical imaging, and genomics analysis. Additionally, NVIDIA’s accelerated software development kits like Parabricks®, MONAI, NeMo™, Riva, and Metropolis are now accessible as NVIDIA CUDA-X™ microservices, further streamlining healthcare workflows.

These microservices are poised to revolutionize healthcare by leveraging generative AI to screen trillions of drug compounds, enhance patient data collection for early disease detection, and implement intelligent digital assistants. Their versatility allows researchers, developers, and practitioners to integrate AI seamlessly into both new and existing applications, regardless of deployment environment.

READ  US FDA Approves Gilead’s Veklury (Remdesivir) Covid-19 Drug For Young Children

Kimberly Powell, NVIDIA’s vice president of healthcare, emphasized the significance of this advancement, stating, “For the first time in history, we can represent the world of biology and chemistry in a computer, making computer-aided drug discovery possible.”

Among the microservices introduced is NVIDIA NIM, which offers optimized inference for various models across healthcare domains, including imaging, medtech, drug discovery, and digital health. These microservices, available through the NVIDIA AI Enterprise 5.0 software platform, include models such as MolMIM for generative chemistry, ESMFold for protein structure prediction, and DiffDock for understanding drug-target interactions.

Furthermore, key players in the industry, such as Cadence, are integrating NVIDIA BioNeMo™ microservices into their platforms to enhance molecular discovery and lead optimization processes. Similarly, pharmaceutical giants like Amgen are leveraging generative AI to revolutionize drug discovery and design processes.

Beyond drug discovery, generative AI is transforming patient care, as exemplified by companies like Hippocratic AI and Abridge. By utilizing NVIDIA’s technology stack, these companies are developing AI-powered healthcare agents and clinical conversation platforms, respectively, to improve patient interactions and streamline clinical workflows.

READ  Experts, Robots to do 39% of Domestic Chores in UK

The availability of these NVIDIA AI microservices enables developers to experiment and deploy production-grade solutions across various platforms, including NVIDIA-Certified Systems™, leading public cloud platforms, and NVIDIA DGX™ Cloud.

For more information, interested parties can visit NVIDIA’s booth at GTC or explore the resources available on their website.